Direct and indirect inhibition by catecholamines of hypocretin/orexin neurons.
Hypothalamic hypocretin enhances arousal, similar to the actions of norepinephrine (NE). The physiological actions of NE were examined in hypocretin neurons identified by selective green fluorescent protein expression in transgenic mouse hypothalamic slices using whole-cell recording. NE induced an outward current, inhibited spike frequency, and hyperpolarized hypocretin neurons dose dependently. Similar actions were evoked by the selective alpha2 adrenergic agonist clonidine. The alpha2 antagonist idazoxan increased spike frequency, suggesting tonic NE-mediated inhibition. The NE-induced current was inwardly rectified, and the reversal potential was dependent on external potassium concentration; it was blocked by barium in the bath and by GTP-gamma-S in the pipette, suggesting activation of a G-protein inward rectifying K+ (GIRK) current. NE and clonidine decreased calcium currents evoked by depolarizing voltage steps. The selective alpha1 adrenergic agonist phenylephrine had no effect on membrane potential but did increase IPSC frequency; miniature IPSC frequency was also increased, in some cells without any effect on amplitude, suggesting a facilitative presynaptic action at alpha1 receptors on GABAergic axons that innervate hypocretin neurons. NE therefore inhibits hypocretin neurons directly through two mechanisms: activation of a GIRK current, depression of calcium currents, and indirectly through increased inhibitory GABA input. Similar to NE, dopamine and epinephrine reduced or blocked spikes and, in the presence of TTX, showed direct hyperpolarizing actions. The action of dopamine was blocked by the D2 receptor antagonist eticlopride, whereas a D1/5 antagonist had no effect. These data suggest that catecholamines evoke strong inhibitory actions on hypocretin neurons and suggest negative feedback from catecholamine cells that may be excited by hypocretin.
Li
Ying
Y
Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
van den Pol
Anthony N
AN
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000375:Aging / Q000502:physiology; D000818:Animals; D015220:Calcium Channels / Q000502:physiology; D002395:Catecholamines / Q000502:physiology; D003000:Clonidine / Q000494:pharmacology; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels; D007031:Hypothalamus / Q000737:chemistry / Q000166:cytology / Q000502:physiology*; D047908:Intracellular Signaling Peptides and Proteins / Q000032:analysis / Q000502:physiology*; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic; D009433:Neural Inhibition / Q000502:physiology; D009474:Neurons / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D009479:Neuropeptides / Q000032:analysis / Q000502:physiology*; D009638:Norepinephrine / Q000502:physiology*; D064446:Orexin Receptors; D000068797:Orexins; D018408:Patch-Clamp Techniques; D010656:Phenylephrine / Q000494:pharmacology; D024661:Potassium Channels, Inwardly Rectifying / Q000502:physiology; D011941:Receptors, Adrenergic / Q000502:physiology; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide; D046509:Tissue Culture Techniques
D000316:Adrenergic alpha-Agonists; D015220:Calcium Channels; D002395:Catecholamines; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D064446:Orexin Receptors; D000068797:Orexins; D024661:Potassium Channels, Inwardly Rectifying; D011941:Receptors, Adrenergic; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide; D010656:Phenylephrine; D003000:Clonidine; D009638:Norepinephrine